Chang Yu-Teng

Mr. Chang Yu-Teng

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Toxins
Verified
Journal Article
Open access
PDF file
CYChang Yu-Teng
Chang Yu-Teng
MCMu-Chi Chung
Mu-Chi Chung
Chang-Chi HsiehChang-Chi Hsieh
Chang-Chi Hsieh
Jeng-Jen ShiehJeng-Jen Shieh
Jeng-Jen Shieh
MWMing-Ju Wu
Ming-Ju Wu
Diabetic nephropathy (DN) is one of the most severe chronic kidney diseases in diabetes and is the main cause of end-stage renal disease (ESRD). Protocatechuic aldehyde (PCA) is a natural product with a variety of effects on pulmonary fibrosis. In this study, we examined the effects of PCA in C57BL/KS db/db male mice. Kidney morphology, renal function indicators, and Western blot, immunohistochemistry, and hematoxylin and eosin (H&E) staining data were analyzed. The results revealed that treatment with PCA could reduce diabetic-induced renal dysfunction, as indicated by the urine albumin-to-creatinine ratio (db/m: 120.1 ± 46.1μg/mg, db/db: 453.8 ± 78.7 µg/mg, db/db + 30 mg/kg PCA: 196.6 ± 52.9 µg/mg, db/db + 60 mg/kg PCA: 163.3 ± 24.6 μg/mg, p < 0.001). However, PCA did not decrease body weight, fasting plasma glucose, or food and water intake in db/db mice. H&E staining data revealed that PCA reduced glomerular size in db/db mice (db/m: 3506.3 ± 789.3 μm2, db/db: 6538.5 ± 1818.6 μm2, db/db + 30 mg/kg PCA: 4916.9 ± 1149.6 μm2, db/db + 60 mg/kg PCA: 4160.4 ± 1186.5 μm2p < 0.001). Western blot and immunohistochemistry staining indicated that PCA restored the normal levels of diabetes-induced fibrosis markers, such as transforming growth factor-beta (TGF-β) and type IV collagen. Similar results were observed for epithelial–mesenchymal transition-related markers, including fibronectin, E-cadherin, and α-smooth muscle actin (α-SMA). PCA also decreased oxidative stress and inflammation in the kidney of db/db mice. This research provides a foundation for using PCA as an alternative therapy for DN in the future.

25 June 2022 in Pharmaceutical Biology
Verified
Journal Article
Open access
CYChang Yu-Teng
Chang Yu-Teng
MCMu-Chi Chung
Mu-Chi Chung
CCChi-Hao Chang
Chi-Hao Chang
KCKuan-Hsun Chiu
Kuan-Hsun Chiu
Jeng-Jen ShiehJeng-Jen Shieh
Jeng-Jen Shieh
MWMing-Ju Wu
Ming-Ju Wu
Protocatechuic aldehyde (PCA) is a natural product that has various benefits for fibrosis.This study evaluated the effects of PCA on renal fibrosis.Epithelial–mesenchymal transition (EMT) was induc...

Verified
Journal Article
Open access
PDF file
MCMu-Chi Chung
Mu-Chi Chung
CYChang Yu-Teng
Chang Yu-Teng
YGYi-Jia Guo
Yi-Jia Guo
CCChi-Jung Chung
Chi-Jung Chung
LWLaing-You Wu
Laing-You Wu
Jeng-Jen ShiehJeng-Jen Shieh
Jeng-Jen Shieh
Contrast-induced acute kidney injury (CIAKI) is a common complication after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (T2DM). The protective role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) against CIAKI remains unclear. We aimed to evaluate the effects of SGLT2i using nationwide database analysis and experimental models. A nationwide nested case–control study using Taiwan’s National Health Insurance Research Database assessed the association between SGLT2i use and risk of post-PCI dialysis. Parallel in vitro experiments examined dapagliflozin in iopamidol-treated HK-2 cells, and in vivo studies tested dapagliflozin in diabetic rats exposed to iopamidol. Clinically, SGLT2i use significantly reduced the risk of post-PCI dialysis (adjusted OR 0.33, 95% CI 0.14–0.76; p = 0.0094). In vitro, dapagliflozin attenuated iopamidol-induced cytotoxicity and NLRP3 inflammasome activation in HK-2 cells. In diabetic rats, dapagliflozin improved renal function, reduced tubular injury, and suppressed inflammasome-driven inflammation. In conclusion, SGLT2i protect against CIAKI by mitigating tubular injury and inflammasome activation. These findings highlight their potential as a preventive strategy for CIAKI in T2DM patients undergoing PCI.

26 June 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CYChang Yu-Teng
Chang Yu-Teng
Chia-Che ChangChia-Che Chang
Chia-Che Chang
MCMing-Jen Chang
Ming-Jen Chang
JSJeng-Jer Shieh
Jeng-Jer Shieh
MWMing-Ju Wu
Ming-Ju Wu

4 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PHPo-Hsun Hou
Po-Hsun Hou
GCGung-Ruei Chang
Gung-Ruei Chang
YCYing-Ting Chao
Ying-Ting Chao
CYChang Yu-Teng
Chang Yu-Teng
DHDa-Han Hou
Da-Han Hou
SHShiau-Shian Huang
Shiau-Shian Huang

18 February 2026 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
JSjia ning syu
jia ning syu
ZLZheng‐Yi Li
Zheng‐Yi Li
SHShi‐Wei Huang
Shi‐Wei Huang
CYChang Yu-Teng
Chang Yu-Teng
CLChih-Sheng Lai
Chih-Sheng Lai
SHShu‐Chung Hsieh
Shu‐Chung Hsieh